Disabled-2 inactivation is an early step in ovarian tumorigenicity

Citation
Z. Fazili et al., Disabled-2 inactivation is an early step in ovarian tumorigenicity, ONCOGENE, 18(20), 1999, pp. 3104-3113
Citations number
37
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ONCOGENE
ISSN journal
09509232 → ACNP
Volume
18
Issue
20
Year of publication
1999
Pages
3104 - 3113
Database
ISI
SICI code
0950-9232(19990520)18:20<3104:DIIAES>2.0.ZU;2-3
Abstract
Disabled-2 (Dab2) functions in mitogenic signal transduction pathway, and i s frequently activated by homozygous gene deletion in tumors, suggesting th at Dab2 is a candidate tumor suppressor. Here, we surveyed the expression o f Dab2 and report that Dab2 is expressed in a variety of tissues, and the l evel of expression is particularly high in ovary and breast. Dab2 expressio n was also detected in immortalized breast and ovarian epithelial cells. Ho wever, in more than a dozen established tumor cell lines derived from breas t and ovarian epithelial tumors examined by Western blotting, Dab2 expressi on was undetectable in 90% of these cell lines. Histological staining of hu man ovarian tissues with specific anti-Dab2 antibodies indicated that Dab2 is highly expressed in the surface epithelial layer, In an immunohistologic al study of 26 ovarian carcinomas, 22 (85%) of the tumors were found to los e the expression of Dab2 in the tumor cells, which are epithelial origin. L oss of Dab2 expression is not correlated with tumor grade, suggesting that Dab2 is lost in an early stage of tumorigenicity. indeed, loss of Dab2 corr elates closely with morphological transformation of the surface epithelial cells. Additionally, loss of Dab2 protein occurs in hyperproliferative, but histological benign ovarian epithelium, suggesting that loss of Dab2 occur s in premalignant lesions. Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding the grade of the tumors, and loss of Dab2 expression is an early event in ovar ian malignancies.